SCHRODER INVESTMENT MANAGEMENT GROUP

Position in KALV — KalVista Pharmaceuticals, Inc.

CIK 1086619 London, X0

Position in KALV

as of Mar 31, 2026 · filed May 14, 2026 Compact

Position Value

$10,200,736

-$8,723,107 QoQ

Shares Held

506,743

-56.8% QoQ

Ownership

0.952%

of shares outstanding

% of Portfolio

0.01%

of 13F equity value

Holder Rank

#32

of 182 holders

Holding Since

Mar 2024

9 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

SCHRODER INVESTMENT MANAGEMENT GROUP holds $603,082,920 across 77 Biotechnology names. KALV ranks #19 (1.7% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	163,898	$73,187,011
2	TECH	BIO-TECHNE Corp	1,197,214	$62,566,403
3	EXEL	Exelixis, Inc.	525,533	$22,540,109
4	ALNY	Alnylam Pharmaceuticals, Inc.	66,662	$22,056,454
5	SLNO	Soleno Therapeutics Inc	648,827	$21,722,727
6	MDGL	Madrigal Pharmaceuticals, Inc.	39,852	$20,861,326
7	INSM	INSMED Inc	119,958	$19,615,531
8	VERA	Vera Therapeutics, Inc.	484,381	$19,486,647

9 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$10,200,736	506,743	-56.8%	Shares	Sole	2026-05-14
2025-12-31	$18,923,843	1,171,755	+1.1%	Shares	Sole	2026-02-13
2025-09-30	$14,110,006	1,158,457	+108.7%	Shares	Sole	2025-11-13
2025-06-30	$6,273,800	554,958	-36.1%	Shares	Sole	2025-08-13
2025-03-31	$10,016,846	868,011	+7.8%	Shares	Sole	2025-05-13
2024-12-31	$6,822,119	805,445	+86.8%	Shares	Sole	2025-02-12
2024-09-30	$4,993,666	431,232	-7.9%	Shares	Sole	2024-11-13
2024-06-30	$5,513,016	467,998	+83.7%	Shares	Sole	2024-08-12
2024-03-31	$3,021,619	254,774	—	Shares	Sole	2024-05-14
No filing history on record for this holder in this stock.